ACAD Valuation

ACADIA Pharmaceuticals Inc

Add to Watchlist

Advanced Chart

25.740

+0.955(3.853%)1D

Overview
Forecast
Valuation
Earnings

ACAD Relative Valuation

ACAD's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, ACAD is overvalued; if below, it's undervalued.

Historical Valuation

ACADIA Pharmaceuticals Inc (ACAD) is now in the Undervalued zone, suggesting that its current forward PS ratio of 0.00 is considered Undervalued compared with the five-year average of -11.48. The fair price of ACADIA Pharmaceuticals Inc (ACAD) is between +Inf to +Inf according to relative valuation methord. Compared to the current price of 25.25 USD , ACADIA Pharmaceuticals Inc is Undervalued By Fair.

Relative Value

Fair Zone

+Inf-+Inf

Current Price：25.25

Fair

Undervalued

43.65

Trailing

Forward

25.98

EV/EBITDA

ACADIA Pharmaceuticals Inc. (ACAD) has a current EV/EBITDA of 25.98. The 5-year average EV/EBITDA is 65.15. The thresholds are as follows: Strongly Undervalued below -553.21, Undervalued between -553.21 and -244.03, Fairly Valued between 374.32 and -244.03, Overvalued between 374.32 and 683.50, and Strongly Overvalued above 683.50. The current Forward EV/EBITDA of 25.98 falls within the Historic Trend Line -Fairly Valued range.

34.76

EV/EBIT

ACADIA Pharmaceuticals Inc. (ACAD) has a current EV/EBIT of 34.76. The 5-year average EV/EBIT is -1.25. The thresholds are as follows: Strongly Undervalued below -113.51, Undervalued between -113.51 and -57.38, Fairly Valued between 54.88 and -57.38, Overvalued between 54.88 and 111.01, and Strongly Overvalued above 111.01. The current Forward EV/EBIT of 34.76 falls within the Historic Trend Line -Fairly Valued range.

3.70

ACADIA Pharmaceuticals Inc. (ACAD) has a current PS of 3.70. The 5-year average PS is 5.65. The thresholds are as follows: Strongly Undervalued below -1.30, Undervalued between -1.30 and 2.17, Fairly Valued between 9.12 and 2.17, Overvalued between 9.12 and 12.60, and Strongly Overvalued above 12.60. The current Forward PS of 3.70 falls within the Historic Trend Line -Fairly Valued range.

17.16

P/OCF

ACADIA Pharmaceuticals Inc. (ACAD) has a current P/OCF of 17.16. The 5-year average P/OCF is -28.36. The thresholds are as follows: Strongly Undervalued below -156.70, Undervalued between -156.70 and -92.53, Fairly Valued between 35.80 and -92.53, Overvalued between 35.80 and 99.97, and Strongly Overvalued above 99.97. The current Forward P/OCF of 17.16 falls within the Historic Trend Line -Fairly Valued range.

21.99

P/FCF

ACADIA Pharmaceuticals Inc. (ACAD) has a current P/FCF of 21.99. The 5-year average P/FCF is -3.65. The thresholds are as follows: Strongly Undervalued below -70.81, Undervalued between -70.81 and -37.23, Fairly Valued between 29.92 and -37.23, Overvalued between 29.92 and 63.50, and Strongly Overvalued above 63.50. The current Forward P/FCF of 21.99 falls within the Historic Trend Line -Fairly Valued range.

ACADIA Pharmaceuticals Inc (ACAD) has a current Price-to-Book (P/B) ratio of 5.12. Compared to its 3-year average P/B ratio of 7.09 , the current P/B ratio is approximately -27.82% higher. Relative to its 5-year average P/B ratio of 7.35, the current P/B ratio is about -30.37% higher. ACADIA Pharmaceuticals Inc (ACAD) has a Forward Free Cash Flow (FCF) yield of approximately 0.00%. Compared to its 3-year average FCF yield of 0.83%, the current FCF yield is approximately -100.00% lower. Relative to its 5-year average FCF yield of -0.98% , the current FCF yield is about -100.00% lower.

5.12

P/B

Median3y

7.09

Median5y

7.35

4.47

FCF Yield

Median3y

0.83

Median5y

-0.98

Competitors Valuation Multiple

The average P/S ratio for ACAD's competitors is 15.99, providing a benchmark for relative valuation. ACADIA Pharmaceuticals Inc Corp (ACAD) exhibits a P/S ratio of , which is -100.00% above the industry average. Given its robust revenue growth of 9.34%, this premium appears unsustainable.

P/S

P/E

EV/EBITDA

EV/EBIT

P/S

Revenue Growth

Market Cap

ACAD.O

ACADIA Pharmaceuticals Inc

Viking Therapeutics Inc

Loss

2.92B

AKRO.O

Akero Therapeutics Inc

Performance Decomposition

Market capitalization of ACAD increased by 55.25% over the past 1 year. The primary factor behind the change was an increase in P/E Change from 10.90 to 18.84.

The secondary factor is the Revenue Growth, contributed 9.34%to the performance.

Overall, the performance of ACAD in the past 1 year is driven by P/E Change. Which is more unsustainable.

9.34%

241.96M → 264.57M

Revenue Growth

-26.96%

13.80 → 10.08

Margin Expansion

72.87%

10.90 → 18.84

P/E Change

55.25%